MeiraGTx Holdings plc Research and Development in Process
MeiraGTx Holdings plc (MGTX) had Research and Development in Process of $7.70 million as of 2020-04-09, per its 10-K filed 2022-03-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2022-03-10
- 2020-04-09: Research and Development in Process $7.70M; Research and Development in Process as first filed $7.69M.
- 2018-10-05: Research and Development in Process $2.99M.
| Period end | Research and Development in Process | Research and Development in Process as first filed |
|---|---|---|
| 2020-04-09 | $7.70M 10-K · filed 2022-03-10 | $7.69M 10-Q · filed 2020-11-05 |
| 2018-10-05 | $2.99M 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |